Literature DB >> 8809446

Lack of correlation among the 3 outcomes describing SLE: disease activity, damage and quality of life.

D D Gladman1, M B Urowitz, A Ong, J Gough, A MacKinnon.   

Abstract

OBJECTIVE: The aim of the this study was to correlate three outcome measures in patients with SLE, namely disease activity, damage, and quality of life.
METHODS: One hundred and five SLE patients completed the Medical Outcome Survey (MOS) SF-20 during their regular clinic visit. Disease activity (SLEDAI) and damage (SLICC/ACR Damage Index) were assessed according to a standard protocol. Statistical analyses included the Pearson correlation coefficients, a logistic regression, and a linear regression analysis.
RESULTS: There was no correlation between the SLEDAI and SLICC/ACR DI. There was no correlation between the SLICC/ACR DI and any of the MOS domains by Pearson correlation. Although a statistical correlation was demonstrated between the SLEDAI score and the social functioning and health perception domains of the MOS SF-20, there were not clinically important.
CONCLUSION: Thus, the three outcomes of disease activity, accumulated damage, and health status remain important independent outcome measures in the assessment of prognosis in patients with SLE.

Entities:  

Mesh:

Year:  1996        PMID: 8809446

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  13 in total

Review 1.  Quality of life in children with systemic lupus erythematosus.

Authors:  L Nandini Moorthy; Margaret Peterson; Karen B Onel; Melanie J Harrison; Thomas J A Lehman
Journal:  Curr Rheumatol Rep       Date:  2005-12       Impact factor: 4.592

2.  Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil.

Authors:  Eutília A M Freire; Inês O Maia; Jamile C A Nepomuceno; Rozana M Ciconelli
Journal:  Clin Rheumatol       Date:  2007-01-10       Impact factor: 2.980

3.  Quality of life in patients with systemic lupus erythematosus (SLE) compared with related controls within a unique African American population.

Authors:  A Barnado; L Wheless; A K Meyer; G S Gilkeson; D L Kamen
Journal:  Lupus       Date:  2011-10-26       Impact factor: 2.911

Review 4.  Quality-of-life measurements versus disease activity in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Michelle Petri
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

Review 5.  Quality-of-life measurements in multiethnic patients with systemic lupus erythematosus: cross-cultural issues.

Authors:  Sergio M A Toloza; Meenakshi Jolly; Graciela S Alarcón
Journal:  Curr Rheumatol Rep       Date:  2010-08       Impact factor: 4.592

6.  Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus.

Authors:  Romela Benitha; Mohammed Tikly
Journal:  Clin Rheumatol       Date:  2006-03-15       Impact factor: 2.980

7.  Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids.

Authors:  X Ng; S dosReis; R Beardsley; L Magder; C D Mullins; M Petri
Journal:  Lupus       Date:  2017-08-31       Impact factor: 2.911

8.  The Chinese version of the SLEQOL is a reliable assessment of health-related quality of life in Han Chinese patients with systemic lupus erythematosus.

Authors:  Hai-Zhi Jiang; Zhi-Guo Lin; Hong-Juan Li; Qing -Du; Wei -Tian; Shu-Ya Wang; Shang-Qi Guan; Yi-Fang Mei
Journal:  Clin Rheumatol       Date:  2017-11-22       Impact factor: 2.980

9.  Predictors of self-reported health-related quality of life in systemic lupus erythematosus.

Authors:  Adnan N Kiani; Vibeke Strand; Hong Fang; Jawali Jaranilla; Michelle Petri
Journal:  Rheumatology (Oxford)       Date:  2013-05-16       Impact factor: 7.580

10.  Quality of life and satisfaction with life in SLE patients-the importance of clinical manifestations.

Authors:  Lilianna Kulczycka; Anna Sysa-Jedrzejowska; Ewa Robak
Journal:  Clin Rheumatol       Date:  2010-06-09       Impact factor: 2.980

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.